NCT00240552已完成4 期
An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 85
- 试验地点
- 13
研究概览
简要总结
This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infected subjects.
- •Subjects must belong to one of the following populations:
- •Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
- •Subjects who already receive amprenavir (Agenerase®)
- •Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.
排除标准
- 未提供
研究者
研究点 (13)
Loading locations...
相似试验
已完成
不适用
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.HIV InfectionsNCT00002173The Immune Response Corporation
Available
不适用
Expanded Access to TriheptanoinLong Chain Fatty Acid Oxidation DisordersNCT03773770Ultragenyx Pharmaceutical Inc
已完成
2 期
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsHIV InfectionsNCT00002234Gilead Sciences25
已完成
3 期
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyHIV InfectionsNCT00004978National Institute of Allergy and Infectious Diseases (NIAID)4,150
进行中（未招募）
4 期
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCNon-squamous NSCLCNCT04413201Michael Hopp34